Costimulation-based immunotherapy for head and neck cancer

Current Treatment Options in Oncology

Volumn 5, Issue 1, 2004, Pages 27-33

  Strome, Scott E ^a   Chen, Lieping ^b  

^a MAYO CLINIC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD137 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CHIMERIC ANTIBODY; HISTONE H1; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR; CD274 PROTEIN, HUMAN; IMMUNOLOGICAL ADJUVANT; LEUKOCYTE ANTIGEN; MEMBRANE PROTEIN; NERVE GROWTH FACTOR RECEPTOR; PEPTIDE; PLASMA PROTEIN; TNFRSF9 PROTEIN, HUMAN;

ANTIGEN ANTIBODY REACTION; ANTINEOPLASTIC ACTIVITY; B LYMPHOCYTE ACTIVATION; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; DRUG TARGETING; GENE EXPRESSION REGULATION; HEAD AND NECK CANCER; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSTIMULATION; LIGAND BINDING; LYMPHOCYTE PROLIFERATION; MORBIDITY; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PATHOGENESIS; QUALITY OF LIFE; REVIEW; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE ACTIVATION; HEAD AND NECK TUMOR; IMMUNOLOGY; IMMUNOTHERAPY; METHODOLOGY;

ADJUVANTS, IMMUNOLOGIC; ANTIGENS, CD; ANTIGENS, CD137; ANTIGENS, CD80; BLOOD PROTEINS; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOTHERAPY; MEMBRANE GLYCOPROTEINS; PEPTIDES; RECEPTORS, NERVE GROWTH FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 1542650910     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-004-0003-9     Document Type: Review

References (36)

1. Strome SE, Voss S, Wilcox R, et al.: Strategies for antigen loading of dendritic cells to enhance the antitumor immune response. Cancer Res 2002, 62:1884-1889.
2. Fields R, Shimizu K, Mule J: Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 1998, 95:9482-9487.
3. Gilboa E, Nair S, Lyerly H: Immunotherapy of cancer with dendritic cell-based vaccines. Cancer Immunol Immunother 1998, 46:82-87.
4. Pardoll D: Cancer vaccines. Nat Med 1998, 4(Suppl 5):525-531.
5. Nestle F, Alijagic S, Gilliet M, et al.: Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998, 4:328-332.
6. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al.: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998, 4:321-327.
7. Chang AE, Redman BG, Whitfield JR, et al.: A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002, 8:1021-1032.
8. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al.: Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res 2001, 61:8513-8519.
9. Nestle F, Banchereau J, Hart D: Dendritic cells: on the move from the bench to bedside. Nat Med 2001, 7:761-765.
10. Chen L, Linsley P, Hellstrom K: Costimulation of T cells for tumor immunity. Immunol Today 1993, 13:483-486.
11. Egen JG, Kuhns MS, Allison JP: CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002, 3:611-618.
12. Hodi FS, Mihm MC, Soiffer RJ, et al.: Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci U S A 2003, 100:4712-4717.
13. Wilcox RA, Flies DB, Zhu G, et al.: Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors. J Clin Invest 2002, 109:651-659.
14. Sica G, Chen L: Modulation of the immune response through 4-1BB. Adv Exp Med Biol 2000, 465:355-362.
15. Saoulli K, Lee S, Cannons J, et al.: CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand. J Exp Med 1998, 187:1849-1862.
16. Melero I, Johnston J, Shufford W, et al.: NK1.1 cells express 4-1BB (CDw137) costimulatory molecule and are required for tumor immunity elicited by anti-4-1-BB monoclonal antibodies. Cell Immunol 1998, 190:167-172.
17. DeBenedette M, Shahinian A, Mak T, Watts T: Costimulation of CD28-T lymphocytes by 4-1BB ligand. J Immunol 1997, 158:551-559.
18. Melero I, Shuford W, Newby S, et al.: Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat Med 1997, 3:682-685.
19. Wilcox RA, Tamada K, Strome SE, Chen L: Signaling through NK cell-associated CD137 promotes both helper function for CD8+ cytolytic T cells and responsiveness to IL-2 but not cytolytic activity. J Immunol 2002, 169:4230-4236.
20. Sun Y, Chen HM, Subudhi SK, et al.: Costimulatory molecule-targeted antibody therapy of a spontaneous autoimmune disease. Nat Med 2002, 8:1405-1413.
21. Jakobovits; A: Production and selection of antigen-specific fully human monoclonal antibodies from mice engineered with human Ig loci. Adv Drug Deliv Rev 1998, 31:33-42.
22. Glennie MJ, Johnson PW: Clinical trials of antibody therapy. Immunol Today 2000, 21:403-410.
23. Hong HJ, Lee JW, Park SS, et al.: A humanized anti-4-1BB monoclonal antibody suppresses antigen-induced humoral immune response in nonhuman primates. J Immunother 2000, 23:613-621.
24. Strome SE, Krauss JC, Chang AE, Shu S: Strategies of lymphocyte activation for the adoptive immunotherapy of metastatic cancer: a review. J Hematother 1993, 2:63-73.
25. Soiffer R, Lynch T, Mihm M, et al.: Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma. Proc Natl Acad Sci U S A 1998, 95:13141-13146.
26. Hayashi T, Tanaka H, Tanaka J, et al.: Immunogenicity and therapeutic efficacy of dendritic tumor hybrid cells generated by electrofusion. Clin Immunol 2002, 104:14-20.
27. Dummer R: GVAX (Cell Genesys). Curr Opin Investig Drugs 2001, 2:844-848.
28. Dong H, Zhu G, Tamada K, Chen L: B7-H1, a third member of the B7 family, costimulates T-cell proliferation and interleukin-10 secretion. Nat Med 1999, 5:1365-1369.
29. Dong H, Strome SE, Salomao DR, et al.: Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002, 8:793-800.
30. Freeman GJ, Long AJ, Iwai Y, et al.: Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000, 192:1027-1034.
31. Latchman Y, Wood CR, Chernova T, et al.: PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001, 2:261-268.
32. Tseng SY, Otsuji M, Gorski K, et al.: B7-DC, a new dendritic cell molecule with potent costimulatory properties for T cells. J Exp Med 2001, 193:839-846.
33. Dong H, Strome SE, Matteson EL, et al.: Costimulating aberrant T cell responses by By-H1 autoantibodies in rheumatoid arthritis. J Clin Invest 2003, 111:363-370.
34. Chen L: Immunological ignorance of silent antigens as an explanation of tumor evasion. Immunol Today 1998, 19:27-30.
35. Hermann T, Patel DJ: Adaptive recognition by nucleic acid aptamers. Science 2000, 287:820-825.
36. Wang S, Bajorath J, Flies DB, et al.: Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med 2003, in press.